CLINICAL TRIALS PROFILE FOR XHANCE
✉ Email this page to a colleague
All Clinical Trials for XHANCE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05275686 ↗ | Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) | Not yet recruiting | Cedars-Sinai Medical Center | Phase 2 | 2022-03-01 | Intranasal nasal steroid sprays are the mainstay of treatment for chronic Eustachian tube dysfunction despite having little supportive evidence in the literature. A novel, commercially available nasal spray delivery system is available now for fluticasone that improves its delivery to the nasopharynx. The hypothesis of this study is that fluticasone using the novel spray system is effective for Eustachian tube dysfunction (ETD). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for XHANCE
Condition Name
Clinical Trial Locations for XHANCE
Trials by Country
Clinical Trial Progress for XHANCE
Clinical Trial Phase
Clinical Trial Sponsors for XHANCE
Sponsor Name